AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17499993 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity‐individualized (HI) training group
Number of subjects: 30
Study 17499993 — intervention group
Group type: COMPARATOR
Intervention: Low intensity‐generalized (LG) training group
Number of subjects: 30
Study 17499993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 16009446 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 102
Study 16009446 — intervention group
Group type: COMPARATOR
Intervention: No probucol treatment
Number of subjects: 102
Study 12492585 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 111
Study 12492585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 10663455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dopamine infusion (2 microg/kg/min)
Number of subjects: 27
Study 10663455 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 27
Study 8860788 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention (11 weeks of daily circuit training exercise and health lecture-discussions)
Number of subjects: 346
Study 8860788 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education volleyball classes
Number of subjects: 346
Study 1310160 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with daily cisplatin (6 mg/m² before radiotherapy)
Number of subjects: 331
Study 1310160 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with weekly cisplatin (30 mg/m² on the first day of each treatment week)
Number of subjects: 331
Study 1310160 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 331
Study 6149738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketazolam
Number of subjects: 50
Study 6149738 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 50
Study 6149738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30560716 — intervention group
Group type: EXPERIMENTAL
Intervention: RAIU-Tg-based activity group (3.26 ± 1.54 GBq)
Number of subjects: 277
Study 30560716 — intervention group
Group type: COMPARATOR
Intervention: Fixed activity group (3.7 GBq)
Number of subjects: 277
Study 30560716 — intervention group
Group type: EXPERIMENTAL
Intervention: RAIU-Tg-based activity group
Number of subjects: 277
Study 30560716 — intervention group
Group type: COMPARATOR
Intervention: Fixed activity group
Number of subjects: 277
Study 29340765 — intervention group
Group type: EXPERIMENTAL
Intervention: PU endotracheal tubes with conical cuff, continuous cuff pressure measurement, continuous subglottic aspiration
Number of subjects: 103
Study 29340765 — intervention group
Group type: COMPARATOR
Intervention: PVC endotracheal tubes with cylindrical cuff, intermittent cuff pressure measurement, intermittent subglottic aspiration
Number of subjects: 103
Study 26612546 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS
Number of subjects: 30
Study 26612546 — intervention group
Group type: COMPARATOR
Intervention: RFA
Number of subjects: 30
Study 25165427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075-mg palonosetron
Number of subjects: 93
Study 25165427 — intervention group
Group type: COMPARATOR
Intervention: 40-mg aprepitant
Number of subjects: 93
Study 21717516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (72 mg-ECP/day)
Number of subjects: 97
Study 21717516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (144 mg-ECP/day)
Number of subjects: 97
Study 21717516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PC)
Number of subjects: 97
Study 18473194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron supplementation
Number of subjects: 0
Study 18473194 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietic Stimulating Agents (ESAs)
Number of subjects: 0
Study 17544845 — intervention group
Group type: EXPERIMENTAL
Intervention: (223)Ra (50 kBq/kg, 4 intravenous injections every 4 weeks)
Number of subjects: 64
Study 17544845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 intravenous injections every 4 weeks)
Number of subjects: 64
Study 17544845 — intervention group
Group type: EXPERIMENTAL
Intervention: (223)Ra
Number of subjects: 64
Study 17544845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15846279 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 3029
Study 15846279 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate (50 mg twice daily)
Number of subjects: 3029
Study 12390633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg)
Number of subjects: 15
Study 12390633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10553915 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ambulatory blood pressure monitoring
Number of subjects: 644
Study 7790472 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG detection using analytical isoelectrofocusing and immunoblotting methods
Number of subjects: 31
Study 1899112 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-oxine
Number of subjects: 12
Study 1899112 — intervention group
Group type: COMPARATOR
Intervention: 111In-tropolone
Number of subjects: 12
Study 6625960 — intervention group
Group type: EXPERIMENTAL
Intervention: Active plasmapheresis
Number of subjects: 10
Study 6625960 — intervention group
Group type: COMPARATOR
Intervention: Sham plasmapheresis
Number of subjects: 10
Study 30919941 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide prolonged release (A-PR)
Number of subjects: 112
Study 30919941 — intervention group
Group type: COMPARATOR
Intervention: Reference product (standard anagrelide)
Number of subjects: 112
Study 30919941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 112
Study 29482964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention trial
Number of subjects: 467
Study 26813472 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 82
Study 26813472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 25122977 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed stabilized stannous fluoride (SnF2) dentifrice (Oral‐B Pro‐Expert, 0.454% SnF2 plus 0.077% NaF)
Number of subjects: 100
Study 25122977 — intervention group
Group type: COMPARATOR
Intervention: Marketed sodium fluoride (NaF)/triclosan dentifrice control (Colgate Total Advanced)
Number of subjects: 100
Study 22433028 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute rewetting period
Number of subjects: 108
Study 22433028 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour rewetting period
Number of subjects: 108
Study 22433028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rewetting stage)
Number of subjects: 108
Study 20838266 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 4640
Study 20838266 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-massage
Number of subjects: 4640
Study 20838266 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical consultation
Number of subjects: 4640
Study 20838266 — intervention group
Group type: EXPERIMENTAL
Intervention: General health service utilization
Number of subjects: 4640
Study 18205096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg/day)
Number of subjects: 406
Study 18205096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 15059705 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% applied four times a day for 3 days before surgery and 1 hour preoperatively
Number of subjects: 130
Study 15059705 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin 1 hour before surgery
Number of subjects: 130
Study 12471565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (Artekin)
Number of subjects: 106
Study 9707165 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled glucocorticoid)
Number of subjects: 10
Study 9707165 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 10
Study 9345404 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon beta (n‐IFN‐beta) 9 MIU three times a week, subcutaneously
Number of subjects: 60
Study 9345404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 2096345 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine hydrochloride 4% solution
Number of subjects: 19
Study 32798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam with benzyl alcohol (0.35 mg/kg diazepam, 1.1 mg/kg benzyl alcohol)
Number of subjects: 0
Study 32798 — intervention group
Group type: COMPARATOR
Intervention: Diazepam without benzyl alcohol (control group)
Number of subjects: 0
Study 31111159 — intervention group
Group type: COMPARATOR
Intervention: Dietary Met/Lys ratio 0.37
Number of subjects: 325
Study 31111159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Met/Lys ratios
Number of subjects: 325
Study 31111159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-prolificacy sows
Number of subjects: 325
Study 28724309 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-guided slow breathing (DGB) for 15 minutes/day for 8 weeks
Number of subjects: 32
Study 28724309 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - music for 8 weeks
Number of subjects: 32
Study 25616551 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (S. salivarius)
Number of subjects: 60
Study 25616551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23140249 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback mouse intervention (vibrates if hand is idle for more than 12 seconds)
Number of subjects: 0
Study 23140249 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback mouse intervention
Number of subjects: 0
Study 22215394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography monitoring
Number of subjects: 24
Study 22215394 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring system
Number of subjects: 24
Study 19825327 — intervention group
Group type: EXPERIMENTAL
Intervention: MEL‐OD (test formulation)
Number of subjects: 26
Study 19825327 — intervention group
Group type: COMPARATOR
Intervention: Mobic (reference formulation)
Number of subjects: 26
Study 19825327 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both formulations
Number of subjects: 26
Study 17763007 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home-based modified carbohydrate dietary intervention (n = 11)
Number of subjects: 23
Study 17763007 — intervention group
Group type: COMPARATOR
Intervention: Group classroom-based modified carbohydrate dietary intervention (n = 12)
Number of subjects: 23
Study 15105212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 90
Study 15105212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alaris auditory evoked potentials (A‐AEP)
Number of subjects: 90
Study 15105212 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed electroencephalogram (pEEG)
Number of subjects: 90
Study 11412776 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial reduction (Group I)
Number of subjects: 19
Study 11412776 — intervention group
Group type: COMPARATOR
Intervention: Control (Group II)
Number of subjects: 19
Study 11412776 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial area and volume in patients with persistent atrial fibrillation (Group I)
Number of subjects: 19
Study 11412776 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial area and volume in patients with normal rhythm (Group I)
Number of subjects: 19
Study 9570426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg and 100 mg
Number of subjects: 5
Study 9570426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 5
Study 9570426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 5
Study 9570426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7934778 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection
Number of subjects: 668
Study 7934778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhalation
Number of subjects: 668
Study 7934778 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhalation
Number of subjects: 668
Study 7934778 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarification
Number of subjects: 668
Study 3146727 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 51
Study 3146727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 51
Study 3146727 — intervention group
Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 51
Study 31402432 — intervention group
Group type: COMPARATOR
Intervention: NMES
Number of subjects: 36
Study 31402432 — intervention group
Group type: COMPARATOR
Intervention: Photobiomodulation therapy
Number of subjects: 36
Study 30378348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Frontomaxillary facial angle (FMFA) measurement
Number of subjects: 0
Study 30378348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal translucency (NT) measurement
Number of subjects: 0
Study 30378348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Frontomaxillary facial angle (FMFA) for diagnosing chromosomal aneuploidy
Number of subjects: 0
Study 26850808 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT)
Number of subjects: 108
Study 26850808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 26850808 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 108
Study 25633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment before menstruation onset (Group A)
Number of subjects: 222
Study 25633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment at the onset of menstruation (Group B)
Number of subjects: 222
Study 25633584 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (Control Group C)
Number of subjects: 222
Study 24000658 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with trimeperidine in combination with nefopam constant infusion
Number of subjects: 60
Study 24000658 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with trimeperidine in combination with nefopam bolus
Number of subjects: 60
Study 24000658 — intervention group
Group type: COMPARATOR
Intervention: Isolated PCA with trimeperidine
Number of subjects: 60
Study 20186397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin
Number of subjects: 50
Study 20186397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18022165 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice per day for 12 weeks)
Number of subjects: 56
Study 18022165 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 16531797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 26
Study 16531797 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 26
Study 12684147 — intervention group
Group type: COMPARATOR
Intervention: TCu 380 A
Number of subjects: 1170
Study 12684147 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380 Nul
Number of subjects: 1170
Study 12684147 — intervention group
Group type: EXPERIMENTAL
Intervention: ML Cu 375 sl
Number of subjects: 1170
Study 10719704 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging of parotid glands
Number of subjects: 16
Study 9211677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg of ganciclovir per hour implant
Number of subjects: 188
Study 9211677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg of ganciclovir per hour implant
Number of subjects: 188
Study 9211677 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 188
Study 1412113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 10 mg/kg every four hours for 48 hours (group A)
Number of subjects: 82
Study 1412113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 2 mg/kg every four hours for 48 hours (group B)
Number of subjects: 82
Study 1412113 — intervention group
Group type: COMPARATOR
Intervention: No intravenous corticosteroids (group C)
Number of subjects: 82
Study 3551969 — intervention group
Group type: EXPERIMENTAL
Intervention: lidamidine HCl
Number of subjects: 32
Study 3551969 — intervention group
Group type: COMPARATOR
Intervention: loperamide
Number of subjects: 32
Study 31416155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/week
Number of subjects: 200
Study 31416155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/week (in subgroup with baseline 25(OH)D <50 nmol/L)
Number of subjects: 200
Study 29136600 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129
Study 29136600 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study 27390052 — intervention group
Group type: EXPERIMENTAL
Intervention: MK0431A 50 mg/500 mg tablet
Number of subjects: 24
Study 27390052 — intervention group
Group type: EXPERIMENTAL
Intervention: MK0431A 50 mg/850 mg tablet
Number of subjects: 24
Study 24758075 — intervention group
Group type: EXPERIMENTAL
Intervention: YTR combined Methotrexate (MTX) + Leflunomide (LEF)
Number of subjects: 88
Study 24758075 — intervention group
Group type: COMPARATOR
Intervention: MTX + LEF therapy
Number of subjects: 88
Study 24758075 — intervention group
Group type: EXPERIMENTAL
Intervention: YTR combined MTX + LEF
Number of subjects: 88
Study 22643324 — intervention group
Group type: EXPERIMENTAL
Intervention: AAQ (artesunate-amodiaquine)
Number of subjects: 12000
Study 22643324 — intervention group
Group type: EXPERIMENTAL
Intervention: AAQ + AMX (artesunate-amodiaquine plus amoxicillin)
Number of subjects: 12000
Study 22643324 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 12000
Study 19760513 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral extravesical ureteroneocystostomy (PLEVUNC)
Number of subjects: 120
Study 19760513 — intervention group
Group type: COMPARATOR
Intervention: Anterior extravesical ureteroneocystostomy (AEVUNC)
Number of subjects: 120
Study 18953863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lamivudine (100 mg/d)
Number of subjects: 40
Study 18953863 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 40
Study 16179038 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.1 MAC
Number of subjects: 25
Study 16179038 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.1 MAC
Number of subjects: 25
Study 12149106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril for 6 weeks
Number of subjects: 0
Study 12149106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril for 6 months
Number of subjects: 0
Study 12149106 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 0
Study 10760037 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha with ribavirin (1-1.2 g per day)
Number of subjects: 304
Study 10760037 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha alone
Number of subjects: 304
Study 7721636 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose irradiation (75.6 CGE) using conformal protons
Number of subjects: 202
Study 7721636 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose irradiation (67.2 Gy) using photons
Number of subjects: 202
Study 1976343 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 180 mg three times daily
Number of subjects: 18
Study 1976343 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 6104133 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory percussion
Number of subjects: 28
Study 6104133 — intervention group
Group type: COMPARATOR
Intervention: Conventional percussion methods
Number of subjects: 28
Study 31742459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-vaccine posts
Number of subjects: 360
Study 31742459 — intervention group
Group type: COMPARATOR
Intervention: Anti-vaccine posts
Number of subjects: 360
Study 31742459 — intervention group
Group type: EXPERIMENTAL
Intervention: Posts with actionable information/resources
Number of subjects: 360
Study 31742459 — intervention group
Group type: EXPERIMENTAL
Intervention: Posts with personal narrative elements
Number of subjects: 360
Study 31742459 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related source posts
Number of subjects: 360
Study 28029173 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 200 mg/d)
Number of subjects: 129
Study 28029173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 25953148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 0
Study 25953148 — intervention group
Group type: COMPARATOR
Intervention: Adult-Driven Applied Behavior Analysis (ABA) Intervention
Number of subjects: 0
Study 23569027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% lidocaine (Group A)
Number of subjects: 120
Study 23569027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33% lidocaine (Group B)
Number of subjects: 120
Study 23569027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (Group C)
Number of subjects: 120
Study 21733570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.5 mg/kg daily for 8 months)
Number of subjects: 40
Study 21733570 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (0.5 mg/kg daily for 8 months)
Number of subjects: 40
Study 19863338 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD consolidation therapy
Number of subjects: 253
Study 19863338 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) consolidation
Number of subjects: 253
Study 19863338 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD and RT for partial responders (PR)
Number of subjects: 253